Covid Vaccine --- Good News For the World first vaccine, the 'milestone' vaccine, provides 90% protection

 Covid vaccine: The good news is that the first vaccine, the 'milestone' vaccine, provides 90% protection.

Pfizer and Bioentech  The first covid-19 vaccine discovered in this effort that will provide 90% protection

 

Covid Updates:

  The first effective coronavirus vaccine may prevent more than 90% of people from receiving Covid-19, the initial analysis noted.

  Developers - Pfizer and Bioentech - have called it a "great day for science and humanity."

  Their vaccine has been tested on 43,500 people in six countries and no safety concerns have been identified.

  The companies plan to apply for emergency approval for use of the vaccine by the end of the month.

  Stock markets have already begun to invest in the news of the Pfizer covid vaccine

 

  Not only will this vaccine work 90% of the time, but it will also benefit the fragile state of the world's economy and society.

  There are about a dozen in the final stages of the test - known as a Phase 3 trial - but this is the first time any results have appeared.

 It uses fully experimental methods - involving injections using parts of the virus's genetic code - to boost the immune system.

  Previous experiments have shown that the vaccine trains the body to produce both antibodies - and another part of the immune system called T-cells to fight the coronavirus.

 

  Two doses are required at three-week intervals.  Trials in the United States, Germany, Brazil, Argentina, South Africa, and Turkey have shown that 90% protection is available seven days after the second dose.

  Pfizer believes it will be able to deliver 50 million doses by the end of this year and about 1.3 billion doses by 2021.

  With another 30 million doses already ordered, 10 million doses have been ordered in the UK by the end of the year.

  However, there are logistical challenges, as the vaccine must be kept in ultra-cold storage below minus 80C.

 No vaccine has proven so effective in such a short time.

  And this vaccine seems to be more effective than people expect.

  The question still remains - how long will the immunity last, will the vaccine work in the body of high-risk older people, will it not stop you from spreading the virus, it will only stop you from developing symptoms?

  The journey ahead is long and complicated.

  Adequate production and then actually vaccinating millions of people around the world is a memorable challenge.

  Preference will be given to hospital and care home staff with the highest risk from Covid-19.

  So face masks and social distances are probably appropriate for some time in our lives.

  But until the end, this darkness of Kovid begins its journey in the hope that one day it may end.

  2px presenter gray line

  Pfizer Chairman Dr. Albert Baurla said: "We are close to an important step in helping people around the world make the much-needed progress to help end this global health crisis."

  Professor Ugur Sahin, one of the founders of Bioentech, described the results as "milestones".

  The data presented is not a final analysis.  It is based on the first 94 volunteers developing Covid - the specific efficacy of the vaccine may change if the full results are analyzed.

 

  Pfizer and Bioentech say they will receive adequate safety information by the third week of November to introduce their vaccine to regulators.  Until then, it will not be possible for countries to start vaccinating them.

  However, the announcement of the companies is a significant development.

  "The news made me laugh from ear to ear," Oxford University professor Peter Harbi said in a statement.

  "It's comforting ... Vaccines have a long way to go before they can start to make a real difference, but it feels like a tidal moment to me."

  The results are "promising" and "the NHS is preparing to begin the process of developing a vaccine program for those most at risk," said an official spokesman for the Prime Minister.